![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TNFRSF9 |
Gene summary for TNFRSF9 |
![]() |
Gene information | Species | Human | Gene symbol | TNFRSF9 | Gene ID | 3604 |
Gene name | TNF receptor superfamily member 9 | |
Gene Alias | 4-1BB | |
Cytomap | 1p36.23 | |
Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | Q07011 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3604 | TNFRSF9 | HCC1 | Human | Liver | HCC | 1.17e-09 | 7.63e-01 | 0.5336 |
3604 | TNFRSF9 | HCC2 | Human | Liver | HCC | 2.33e-16 | 1.44e+00 | 0.5341 |
3604 | TNFRSF9 | HCC5 | Human | Liver | HCC | 3.66e-16 | 1.33e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | Breast | DCIS |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | Breast | Healthy |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | Cervix | CC |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | Cervix | Precancer |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | CRC | MSI-H |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | Endometrium | ADJ |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | Endometrium | AEH |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | HNSCC | OSCC |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | HNSCC | Precancer |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | Prostate | BPH |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | Prostate | Tumor |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | THCA | ADJ |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | THCA | Cancer |
TNFSF9 | TNFRSF9 | TNFSF9_TNFRSF9 | CD137 | THCA | PTC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNFRSF9 | SNV | Missense_Mutation | rs777538728 | c.476N>A | p.Gly159Glu | p.G159E | Q07011 | protein_coding | deleterious(0) | possibly_damaging(0.738) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
TNFRSF9 | SNV | Missense_Mutation | rs759670379 | c.379G>A | p.Asp127Asn | p.D127N | Q07011 | protein_coding | tolerated(0.21) | benign(0.095) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
TNFRSF9 | SNV | Missense_Mutation | rs186372948 | c.401N>A | p.Arg134Gln | p.R134Q | Q07011 | protein_coding | tolerated(0.19) | benign(0.026) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNFRSF9 | SNV | Missense_Mutation | c.137G>A | p.Ser46Asn | p.S46N | Q07011 | protein_coding | tolerated(0.53) | benign(0.043) | TCGA-D1-A160-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TNFRSF9 | SNV | Missense_Mutation | rs143524950 | c.643N>T | p.Arg215Trp | p.R215W | Q07011 | protein_coding | tolerated(1) | benign(0) | TCGA-KP-A3W0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNFRSF9 | SNV | Missense_Mutation | c.715N>C | p.Asp239His | p.D239H | Q07011 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-55-A48Y-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR | |
TNFRSF9 | SNV | Missense_Mutation | c.577N>T | p.Ala193Ser | p.A193S | Q07011 | protein_coding | tolerated(0.19) | benign(0.137) | TCGA-55-A490-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD | |
TNFRSF9 | SNV | Missense_Mutation | c.380A>G | p.Asp127Gly | p.D127G | Q07011 | protein_coding | tolerated(0.06) | benign(0.089) | TCGA-78-7156-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
TNFRSF9 | SNV | Missense_Mutation | rs201133913 | c.34C>G | p.Leu12Val | p.L12V | Q07011 | protein_coding | tolerated(1) | benign(0) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TNFRSF9 | SNV | Missense_Mutation | c.416N>T | p.Cys139Phe | p.C139F | Q07011 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-18-3416-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3604 | TNFRSF9 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE | PF-05082566 | UTOMILUMAB | ||
3604 | TNFRSF9 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE | CD137 CAR-T Cell | |||
3604 | TNFRSF9 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE | antibody | 318164830 | URELUMAB | |
3604 | TNFRSF9 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE | CD28 and CD137 CAR-T Cells | |||
3604 | TNFRSF9 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE | Urelumab | URELUMAB | ||
3604 | TNFRSF9 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE | antibody | 315661319 | UTOMILUMAB | |
3604 | TNFRSF9 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE | 178101774 | |||
3604 | TNFRSF9 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE | MG7-CART | |||
3604 | TNFRSF9 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE | agonist | CHEMBL1743085 | URELUMAB | |
3604 | TNFRSF9 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE | Anti-CD137 |
Page: 1 |